EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

January 26, 2016 updated by: Bristol-Myers Squibb

A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C

The primary objective of this program is to provide Daclatasvir in combination with Sofosbuvir with or without Ribavirin to subjects with chronic Hepatitis C who are at a high risk of liver decompensation or death within 12 months if left untreated and who have no available therapeutic options.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
No longer available

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Expanded Access

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
      • Amstetten, Austria
        • Local Institution
      • Braunua/Inn, Austria
        • Local Institution
      • Graz, Austria
        • Local Institution
      • Innsbruck, Austria
        • Local Institution
      • Linz, Austria
        • Local Institution
      • Oberndorf, Austria
        • Local Institution
      • Oberpullendorf, Austria
        • Local Institution
      • Salzburg, Austria
        • Local Institution
      • Vienna, Austria
        • Local Institution
      • Wien, Austria
        • Local Institution
  • Germany
      • Aachen, Germany
        • Local Institution
      • Augsburg, Germany
        • Local Institution
      • Berlin, Germany
        • Local Institution
      • Bonn, Germany
        • Local Institution
      • Cologne, Germany
        • Local Institution
      • Essen, Germany
        • Local Institution
      • Frankfurt, Germany
        • Local Institution
      • Frankfurt Am Main, Germany
        • Local Institution
      • Hamburg, Germany
        • Local Institution
      • Hannover, Germany
        • Local Institution
      • Heidelberg, Germany
        • Local Institution
      • Herne, Germany
        • Local Institution
      • Jena, Germany
        • Local Institution
      • Kiel, Germany
        • Local Institution
      • Leipzig, Germany
        • Local Institution
      • Muenchen, Germany
        • Local Institution
      • Muenster, Germany
        • Local Institution
      • Munchen, Germany
        • Local Institution
      • Stuttgart, Germany
        • Local Institution
      • Tuebingen, Germany
        • Local Institution
      • Ulm, Germany
        • Local Institution
      • Wuerzburg, Germany
        • Local Institution
  • Netherlands
      • Amsterdam, Netherlands
        • Local Institution
      • Rotterdam, Netherlands
        • Local Institution
      • Urecht, Netherlands
        • Local Institution
  • Sweden
      • Falun, Sweden
        • Local Institution
      • Gothenburg, Sweden
        • Local Institution
      • Helsingborg, Sweden
        • Local Institution
      • Kalmar, Sweden, SE-391 85
        • Local Institution
      • Lulea, Sweden
        • Local Institution
      • Lund, Sweden
        • Local Institution
      • Stockholm, Sweden
        • Local Institution
      • Sundsvall, Sweden
        • Local Institution
  • United Kingdom
      • Brighton, United Kingdom
        • Local Institution
      • Cardiff, United Kingdom
        • Local Institution
      • Frimley, United Kingdom
        • Local Institution
      • Guildford, United Kingdom
        • Local Institution
      • London, United Kingdom
        • Local Institution
      • Wrexham, United Kingdom
        • Local Institution
    • Devon
      • Plymouth, Devon, United Kingdom
        • Local Institution
    • Greater London
      • London, Greater London, United Kingdom
        • Local Institution
    • Greater Manchester
      • Manchester, Greater Manchester, United Kingdom
        • Local Institution
    • Merseyside
      • Liverpool, Merseyside, United Kingdom, L7 8XP
        • Local Instituition
    • Nottinghamshire
      • Nottingham, Nottinghamshire, United Kingdom
        • Local Institution
    • Oxfordshire
      • Oxford, Oxfordshire, United Kingdom
        • Local Institution
    • Tyne And Wear
      • Newcastle Upon Tyne, Tyne And Wear, United Kingdom
        • Local Institution
    • West Midlands
      • Birmingham, West Midlands, United Kingdom
        • Local Institution
    • Yorkshire
      • Leeds, Yorkshire, United Kingdom
        • Local Institution

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Description

This program is conducted in the EU (Germany, Austria, Norway, The Netherlands, Sweden and United Kingdom only)

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Patients chronically infected with Hepatitis C
  • Patients at a high risk of liver decompensation or death within 12 months if left untreated and who have no available therapeutic options

Exclusion Criteria:

  • Patients who are <18 years old
  • Patients who have contraindications to either Daclatasvir (DCV) or Sofosbuvir (SOF)
  • Patients who are pregnant
  • Creatinine clearance (CrCl) ≤ 30 mL/min (as estimated by Cockcroft and Gault formula)
  • Patients who are pregnant or Women of Child Bearing Potential who are not using required contraception

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Bristol-Myers Squibb

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 25, 2014

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 25, 2014

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 27, 2014

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 27, 2016

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 26, 2016

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • AI444-237

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings